Cite
Precisely albumin-hitchhiking tumor cell-activated reduction/oxidation-responsive docetaxel prodrugs for the hyperselective treatment of breast cancer.
MLA
Wei, Wei, et al. “Precisely Albumin-Hitchhiking Tumor Cell-Activated Reduction/Oxidation-Responsive Docetaxel Prodrugs for the Hyperselective Treatment of Breast Cancer.” Journal of Controlled Release, vol. 285, Sept. 2018, pp. 187–99. EBSCOhost, https://doi.org/10.1016/j.jconrel.2018.07.010.
APA
Wei, W., Luo, C., Yang, J., Sun, B., Zhao, D., Liu, Y., Wang, Y., Yang, W., Kan, Q., Sun, J., & He, Z. (2018). Precisely albumin-hitchhiking tumor cell-activated reduction/oxidation-responsive docetaxel prodrugs for the hyperselective treatment of breast cancer. Journal of Controlled Release, 285, 187–199. https://doi.org/10.1016/j.jconrel.2018.07.010
Chicago
Wei, Wei, Cong Luo, Jincheng Yang, Bingjun Sun, Dongyang Zhao, Yan Liu, Yingli Wang, et al. 2018. “Precisely Albumin-Hitchhiking Tumor Cell-Activated Reduction/Oxidation-Responsive Docetaxel Prodrugs for the Hyperselective Treatment of Breast Cancer.” Journal of Controlled Release 285 (September): 187–99. doi:10.1016/j.jconrel.2018.07.010.